Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma

Christiane Pott(University Hospital Schleswig-Holstein), Michael Kneba(Universitäts Hautklinik Kiel), Markus Tiemann(European Central Bank), Martin Dreyling(LMU Klinikum), Thorsten Raff(Goethe University Frankfurt), Matthias Ritgen(Goethe University Frankfurt), Lana Harder(Franklin University), B. Gahn(Houston Methodist), Peter Dreger(Heidelberg University), Reiner Siebert(Universität Ulm), Carsten Schrader(Heidelberg University), Wolfgang Hiddemann(Christian-Albrechts-Universität zu Kiel), Michael Unterhalt, Monika Brüggemann(University Hospital Schleswig-Holstein), Stefan Gesk(Christian-Albrechts-Universität zu Kiel)
Blood
December 7, 2005
10.1182/blood-2005-07-2845
Cited by 162

Related Papers

Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936
|Leukemia|2003|3k
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
|The Lancet|2019|2.6k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
A Biologic Definition of Burkitt's Lymphoma from Transcriptional and Genomic Profiling
|New England Journal of Medicine|2006|1k
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma
|Blood|2007|971